Can Bosutinib treat ALS?

Bosutinib (Bosutinib) is mainly used to treat chronic myelogenous leukemia (CML). It is a tyrosine kinase inhibitor. There is currently no clear evidence that bosutinib has significant efficacy in the treatment of ALS (Amyotrophic Lateral Sclerosis, ALS).

ALS is a rare but serious neurological disorder characterized by progressive neuronal damage that causes patients to gradually lose control of their muscles, ultimately affecting their respiratory muscles. The methods for treating ALS are currently relatively limited, mainly improving patients’ quality of life through symptomatic treatment and rehabilitation care.

Tyrosine kinase inhibitor drugs are usually designed to interfere with abnormal cell proliferation, such as in malignancies such as leukemia. The disease mechanisms associated with ALS are very different from those of leukemia, so the use of this type of drug in the treatment of ALS is still in the early stages of research and has not yet been widely proven.

However, the field of scientific research is constantly evolving, and new treatment strategies and drug developments may emerge in the future. For treatment of ALS, patients should rely on the latest medical research and their doctor's advice. If there is any latest research on bosutinib or other drugs in treating ALS, it is recommended to consult a professional doctor or check the latest medical literature.

Bosutinib is not yet available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs of bosutinib abroad. The original drugs include the Turkish original drug and the European version of the original drug. The Turkish version of the original drug costs about 2,000 to 3,000 yuan, and the European version of the original drug costs about 30,000 yuan. In addition, there are cheaper generic drugs, which cost more than one thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.